Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Posted By Global Banking and Finance Review

Posted on January 17, 2025

Recordati and its top investor say no plans for deal with Angelini

MILAN (Reuters) - Recordati and its top shareholder CVC Capital Partners on Friday denied any plans to combine the Italian drugmaker with smaller rival Angelini Pharma.

"CVC Capital Partners... is not contemplating a transaction with Angelini Pharma or its shareholders," CVC said in a joint statement with Recordati.

The private equity firm and the drugmaker said there were no contacts with Angelini, adding they did "not envisage any dialogue taking place in the future with either the management or the shareholders of Angelini Pharma."

The comments came after reports in the Italian press this week about a potential tie-up between the two drug firms.

On Friday, Italian daily Il Sole 24 Ore said that the family that owns Angelini Pharma could transfer its pharmaceutical business into a new company and then merge that with rival Recordati. The paper said both sovereign and pension funds had been sounded out about a potential co-investment in the venture.

In November, following an earlier report about the potential tie-up, Angelini Pharma declined to comment on its possible interest for Recordati, adding it "always looks at all market opportunities."

Recordati has a market capitalization of more than 11 billion euros.

(Reporting by Elvira Pollina and Elisa Anzolin, editing by Giulia Segreti and Valentina Za)

Recommended for you

  • Goldman Sachs boosts CEO pay to $39 million, lines up five more years at helm

  • AstraZeneca overhauls management of its China division, FT reports

  • Polish president signs budget but sends it to Constitutional Tribunal